Influence of Neoadjuvant Therapy with Epirubicin and Docetaxel on the Expression of HER2/neu in Patients with Breast Cancer

被引：0
|
作者：
Susanne Taucher
Margaretha Rudas
Robert M. Mader
Michael Gnant
Emanuel Sporn
Peter Dubsky
Sebastian Roka
Thomas Bachleitner
Florian Fitzal
Daniela Kandioler
Catharina Wenzel
Günther G. Steger
Martina Mittlböck
Raimund Jakesz
机构：
[1] Vienna University Medical School,Department of Surgery
[2] Vienna University Medical School,Department of Pathology
[3] Vienna University Medical School,undefined
来源：
Breast Cancer Research and Treatment | 2003年 / 82卷
关键词：
breast cancer; core needle biopsy; docetaxel; epirubicin; FISH; HER2/; immunohistochemistry; preoperative treatment; trastuzumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Background. In primary breast cancer, the expression levels of biological markers relevant to the progression of the disease may be altered by administration of anticancer drugs. Since neoadjuvant chemotherapy with epirubicin and docetaxel is increasingly used in advanced breast cancer, our purpose was to assess the influence of this neoadjuvant chemotherapy on the expression of the growth factor receptor HER2/neu.
引用
收藏
页码：207 / 213
页数：6
相关论文
共 50 条
  • [31] The association of higher tumor HER2 load with treatment response to neoadjuvant therapy in HER2 positive breast cancer patients
    Lillemoe, T. J.
    Susnik, B.
    Grimm, E.
    Kang, S-H L.
    Swenson, K. K.
    Krueger, J. L.
    Finkelstein, M. J.
    Tsai, M. L.
    CANCER RESEARCH, 2017, 77
  • [32] Stability of HER2 Expression in Residual Breast Cancer Following Neoadjuvant Anti-HER2 Therapy.
    Mir, Mariam O.
    Sahoo, Sunati
    Fang, Yisheng
    Peng, Yan
    Hwang, Helena
    Czapla, Agata
    Koduru, Prasad
    Sarode, Venetia
    MODERN PATHOLOGY, 2018, 31 : 91 - 91
  • [33] Study of oncogen HER2/neu in breast cancer
    San Miguel, Angel
    Martin, Lourdes
    San Miguel-Hernandez, Rafael
    Gonzalez Blanco, Ignacio
    Martin-Gil, Francisco J.
    GINECOLOGIA Y OBSTETRICIA CLINICA, 2008, 9 (02): : 83 - 91
  • [34] Can lipophilic statins affect Her2/neu expression in breast cancer?
    Gupta, S.
    Desai, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [35] HER2/neu in the management of invasive breast cancer
    Meric, F
    Hung, MC
    Hortobagyi, GN
    Hunt, KK
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2002, 194 (04) : 488 - 501
  • [36] Her2/neu Overexpressing Breast Cancer Patients Retain an Immunological Proficiency Compromised in Her2/neu-Negative Cases
    Simona, S. S. S.
    Muraro, E. M. E.
    Miolo, G. G. M.
    Martorelli, D. M. D.
    Turchet, E. T. E.
    Comaro, E. C. E.
    Talamini, R. T. R.
    Veronesi, A. V. A.
    Crivellari, D. C. D.
    Dolcetti, R. D. R.
    CANCER RESEARCH, 2010, 70
  • [37] HER2:: The Neu prognostic marker for breast cancer
    Tsongalis, GJ
    Ricci, A
    CRITICAL REVIEWS IN CLINICAL LABORATORY SCIENCES, 2001, 38 (02) : 167 - 182
  • [38] HER2/neu as a predictive factor in breast cancer
    Piccart, M
    Hamilton, A
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S84 - S84
  • [39] The effect of neoadjuvant chemotherapy on hormone receptor status, HER2/neu and prolactin in breast cancer
    Pedrini, Jose Luiz
    Savaris, Ricardo Francalacci
    Schorr, Mario Casales
    Cambruzi, Eduardo
    Grudzinski, Melina
    Zettler, Claudio Galleano
    TUMORI JOURNAL, 2011, 97 (06): : 704 - 710
  • [40] Impact of neoadjuvant HER2-directed therapy on HER2 status in breast cancer
    Manguso, Nicholas
    Johnson, Jeffrey
    Basho, Reva Kakkar
    McArthur, Heather L.
    Tanaka, Hisashi
    Giuliano, Armando E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345